Table 1.

Effect of cannabinoids on oligodendrocyte progenitor survival after deprivation of trophic support

TreatmentA2B5+ cells (% of control)MTT assay (% of control)LDH release (% of total)TUNEL+ cells (% of total)Condensed nuclei (% of total)Caspase-3+ cells (% of total)
CTL (PDGF + bFGF)100  ± 2.6100  ± 3.53.33  ± 0.82.18  ± 0.21.3  ± 0.61.67  ± 0.6
DMEM + F12 (DF)53.6  ± 5.1*56.3  ± 1.2*34.3  ± 5.8*23.7  ± 1.5*18.0  ± 1.6*20.2  ± 1.8*
DF + HU21080.4  ± 5.71-24780.3  ± 2.61-1598.00  ± 1.01-1593.70  ± 0.31-1592.30  ± 0.31-1592.36  ± 0.31-159
DF + Win 55212-283.0  ± 6.41-24786.3  ± 2.21-15910.6  ± 0.81-1594.40  ± 0.41-1593.20  ± 0.31-1591.78  ± 0.41-159
  • Oligodendrocyte progenitors were cultured for 2 d in serum-free defined medium plus 5 ng/ml of both PDGF and bFGF and then switched to DMEM/F12 (DF) medium alone without growth supplements for 12 hr in the presence or absence of the nonselective cannabinoid agonists HU210 (500 nm) or (+)-Win 55212-2 (25 nm). The MTT and LDH data are the mean ± SEM of four independent experiments performed in triplicate. Quantification of condensed nuclei, A2B5-, TUNEL-, and caspase-3-positive cells was obtained from at least eight coverslips (5 microscopic fields/coverslip), and results are the mean ± SEM of four independent cultures. A minimum of 1500 cells was counted per coverslip. Statistical differences:

  • * p < 0.001 DMEM + F12 (DF) versus control cells (with PDGF and bFGF);

  • F1-159 p < 0.001 DF + HU210 or DF + Win55212-2 versus DF;

  • F1-247 p < 0.01 DF + HU210 or DF + Win55212-2 versus DF.